Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 93 of the 100 references it cites were found in a registry or an index; 60 of the 81 sources its claims cite were checked for support.
Abstract
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D/+; Trp53LSL-R172H/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018.
Overview
CoChat Summary
TL;DR
This multimodal study defines heterogeneous genetic and non-genetic resistance mechanisms to mutant-selective KRAS inhibition in pancreatic ductal adenocarcinoma (PDAC), using patient ctDNA and preclinical models. It finds recurrent RTK–RAS/PI3K pathway alterations, cell-cycle/efflux amplifications, and a drug-resistant partial EMT cell state, supporting combination strategies with chemotherapy or RTK/CLDN18.2-directed agents.
Key findings
- In 22 patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, 18/22 (81%) had PR/SD and acquired resistance, 4/22 had primary resistance, and putative genetic resistance mechanisms were identified in 9/22 (41%); across an aggregate KRASG12C cohort, genetic mechanisms were found in 51% of NSCLC, 52% of CRC, 46% of PDAC, and 75% of other GI cancers, while no putative genetic mechanism was identified in 54% of PDAC, 49% of NSCLC, and 48% of CRC.
- In preclinical models, MRTX1133 selectively inhibited KRASG12D-mutant cells across 877 PRISM cell lines; among 46 KRASG12D lines, 22 were sensitive and 24 resistant by AUC, with resistance associated with EMT, RTK–RAS pathway gene copy gains, PI3K–AKT–mTOR activation, and MYC/cell-cycle signatures.
- In the autochthonous KPC GEMM, MRTX1133 prolonged median survival to 10.7 weeks versus 1 week for vehicle (P = 2.08e–6), with complete responses in 67% (10/15), PRs in 27% (4/15), and primary resistance in 1/15; 55% (6/11) of endpoint MRTX1133-resistant tumors had high-level amplifications including Myc, Kras, Yap1, and Cdk6/Abcb1a/b.
- Single-nucleus RNA-seq of 68,479 nuclei showed MRTX1133-resistant tumors shifted toward pEMT (60% of nuclei) and mesenchymal (30%) states, and combination MRTX1133 plus gemcitabine/n(ab)-paclitaxel prevented relapse in orthotopic and metastatic models, with no lung metastases in combination-treated mice in the established-metastasis assay.
Methods
- Patient ctDNA from pretreatment and end-of-therapy plasma was sequenced from patients with KRASG12C-mutant PDAC treated on KRYSTAL-1 (adagrasib) or CodeBreaK100 (sotorasib), plus additional GI cancer samples and previously published KRASG12C inhibitor resistance cohorts.
- Preclinical profiling included PRISM multiplex cell-line screening (877 lines), KRASG12D-mutant PDAC patient-derived organoids (n = 20), isogenic MRTX1133-resistant cell lines, KPC GEMMs, PDX models, WES, bulk RNA-seq, snRNA-seq, RPPA, RTK arrays, immunoblots, IHC, and multiplex immunofluorescence.
- Analyses included AUC/dose-response modeling, GSEA, NMF metaprogram identification, inferCNV, pySCENIC regulon analysis, Markov absorption-based cell-state classification, and survival/statistical comparisons as described.
Limitations
- Stated: human PDAC resistance analysis relied primarily on ctDNA, and the authors note that future biopsies from patients progressing on RAS inhibitors are needed to fully interrogate genetic and non-genetic resistance.
- Stated: preclinical studies focused on the KRASG12D inhibitor MRTX1133; resistance mechanisms need evaluation with pan-RAS/pan-KRAS inhibitors and drugs of different selectivity/mechanism to define cross-resistance patterns.
- Evident from the text: the patient cohort is described as rare and limited to 22 PDAC patients, ctDNA-based detection may miss resistance drivers, and some resistant tumors/subclones lacked identifiable genomic drivers, leaving non-genetic mechanisms incompletely resolved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
28 Valid · 0 Not valid · 6 Not checked · 168 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additional investigations of combination therapy strategies with MRTX1133 in preclinical models of PDAC have suggested that co-targeting of EGFR may have enhanced efficacy over monotherapy (30, 34).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Supportedcites [30] Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD,. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 2022; 28: 2171– 82. 36216931 source
In the section on cetuximab combinations, the paper reports that cetuximab, an EGFR-targeting antibody, improved the anti-tumor efficacy of MRTX1133 over either agent alone in all seven pancreatic or colon xenograft models evaluated. It also reports stronger pathway inhibition in the AsPC-1 pancreatic cancer model, supporting the claim's qualified statement about preclinical PDAC models. (LLM, conf=0.94)
- Supportedcites [34] Gulay KCM, Zhang X, Pantazopoulou V, Patel J, Esparza E, Pran Babu DS,. Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res 2023; 83: 3001– 12. 37378556 PMC10502451 source
The “Irreversible pan-ERBB inhibitors synergize with MRTX1133 in vitro” section reports synergy in PDAC models with EGFR-targeting agents, although it was less consistent than with pan-ERBB inhibition. The “KRAS G12D-mutant PDAC cells” section reports greater tumor-growth inhibition with MRTX1133 plus afatinib than with MRTX1133 alone in transplant models. Together, these findings support the hedged claim of enhanced efficacy, with the qualification that the strongest evidence is for pan-ERBB rather than EGFR-only inhibition. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although these early clinical trial results need to be confirmed in larger studies, the efficacy of sotorasib and adagrasib in advanced, chemotherapy-treated disease compares favorably to historical data on second-line chemotherapy efficacy in PDAC, where response rates are consistently less than 10% and median PFS is less than 3 months (28, 29).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Not checked — no full text of the sourcecites [28] Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA,. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019; 108: 78– 87. 30654298 source
- Partly supportedcites [29] Huffman BM, Basu Mallick A, Horick NK, Wang-Gillam A, Hosein PJ, Morse MA,. Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial. JAMA Netw Open 2023; 6: e2249720. 36602796 PMC9856813 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates an associationn = 38- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent preclinical work with MRTX1133 has demonstrated excellent responses in cell line and xenograft models of PDAC (30, 32).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Supportedcites [30] Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD,. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 2022; 28: 2171– 82. 36216931 source
The section on KRASG12D-mutant cancer cell lines reports potent inhibition of cell viability by MRTX1133. The xenograft-results section reports at least 30% tumor regression in 8 of 11 pancreatic cancer models. Our copy provides no page numbers for these passages. (LLM, conf=0.92)
- Supportedcites [32] Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B,. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell 2023; 41: 1606– 20.e8. 37625401 PMC10785700 source
The section ‘KRAS* inhibition suppresses the growth of human PDAC cells’ (page not available) reports that MRTX1133 inhibited proliferation in KRAS G12D-mutant PDAC cell lines. It also reports significantly reduced tumor weights in orthotopic xenografts and tumor control or slight regression in all eight patient-derived xenografts. (LLM, conf=0.91)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
What the sources say
- Supportedcites [44] Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE,. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 2021; 184: 6119– 37.e26. 34890551 PMC8822455 source
The Results section, “State-specific TME signals drive transcriptional heterogeneity and drug response” (page unavailable), reports clinical trial data in which patients with basal phenotypes tended to have poorer outcomes with combination chemotherapy. It also reports that organoids in a basal state were less sensitive to several chemotherapies than when they returned to a classical state. Together, these support the claim’s cautious comparison. (LLM, conf=0.91)
- Supportedcites [58] Aung KL, Fischer SE, Denroche RE, Jang G-H, Dodd A, Creighton S,. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res 2018; 24: 1344– 54. 29288237 PMC5968824 source
The Results report more partial responses to first-line chemotherapy in classical than basal-like tumors (13/38 versus 1/12). The Discussion explicitly states that patients with advanced classical PDAC responded better than those with basal-like PDAC; the Results also report shorter survival for the basal-like subtype. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Supportedcites [59] O’Kane GM, Grünwald BT, Jang G-H, Masoomian M, Picardo S, Grant RC,. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res 2020; 26: 4901– 10. 32156747 source
The ‘Response to chemotherapy according to modified Moffitt classification’ section reports a higher overall response rate in classical than basal-like PDAC (33% versus 10%, p=0.02). The ‘Overall survival’ section reports shorter survival for the basal-like subgroup receiving mFFX and identifies subtype as prognostic; it found no survival difference between subgroups receiving GnP, so the claim is appropriately framed as a suggestion rather than a benefit with every regimen. (LLM, conf=0.92)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Finally, we identified a novel partial EMT (pEMT) signature analogous to previously described hybrid states along the epithelial–mesenchymal axis (Supplementary Fig. S8A; refs. 50, 53).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Malignant Cell State Evolution in Response and Resistance to KRASG12D Inhibition
What the sources say
- Not checked — no full text of the sourcecites [50] Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R,. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 2023: 618; 598– 606. 37258682 source
- Supportedcites [53] Barkley D, Moncada R, Pour M, Liberman DA, Dryg I, Werba G,. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet 2022; 54: 1192– 201. 35931863 PMC9886402 source
The Results describe a partial mesenchymal (pEMT) module distinct from a complete mesenchymal module and note that pEMT had previously been characterized in other cancer types. This supports the citation’s comparison to previously described partial EMT states; the citing authors’ identification of a novel signature is their own finding, not a finding attributed to this source. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
104 more claims · 7 with their cited sources checked
Create a free account to see all 202 claims and to verify the 2 references still open.
- It may state two separate claims as one. 68
- Probably not a substantial claim. 32
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the established role of lineage plasticity in resistance to KRAS-targeted therapies,26–31 effective therapeutic interventions targeting drivers of lineage plasticity remain lacking.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Differentiation into alveolar type 1 (AT1)-like,26 squamous,27,28 as well as mucinous states29 has been implicated to contribute to KRAS inhibitor tolerance in lung adenocarcinoma, whereas transition into a classical state is observed in PDAC cells surviving KRAS-targeted therapy.30,31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lineage plasticity has emerged as a critical mechanism of non-genetic resistance to KRAS-targeted therapies in NSCLC and PDAC.27–31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In NSCLC, KRAS-mutant tumors evade therapy through transition into AT1-like,29 squamous,27,28 or mucinous states,29 while pancreatic cancer cells adopt a classical epithelial state to bypass KRAS inhibition.30,31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic alterations, especially secondary RAS mutations, have been identified as one of the most common mechanisms of acquired resistance to KRAS inhibitors in patients [49, 51–55].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [55]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Methods > In Vivo Protocols
“100% to 76% = 4”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Methods > In Vivo Protocols
“51% to 76% = 3”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
“In vivo, 6649C2-LM implanted subcutaneously grows slightly more rapidly than the parental cell line, showing overall more aggressive growth and faster outgrowth under MRTX1133 treatment (Fig. 6D).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
“We previously generated a transplantable cell line model of metastatic PDAC (6694C2-LM) by isolating and culturing a tumor nodule from a spontaneous lung metastasis of a 6649C2 tumor-bearing mouse (60).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Genetic Mechanisms of Resistance to KRASG12C Inhibition in Patients with PDAC
“C, Co-mutation plot displaying pathogenic and likely pathogenic treatment-emergent variants and genomic amplification of putative drivers of resistance detected in ctDNA samples from PDAC patients with acquired resistance to adagrasib (patients 1–8) or sotorasib (patients 9–22).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Genetic Mechanisms of Resistance to KRASG12C Inhibition in Patients with PDAC
“Primary resistance with PD was observed in 4/22 patients (patients 1, 9, 10, 11).”
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“79 ; version 1.38.3) log-normalized tumor-derived expression profiles.”
InfluentialFiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890 · cited 1×
“Finally, individual dot densitometry analysis was conducted using Fiji image analysis software (83). snRNA-seq Sample Preparation, Library Generation, and Sequencing.”
MethodNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“…was determined based on routine clinical evaluation by a blinded, board-certified radiologist and defined as SD for at least 12 weeks or a partial or complete response followed by disease progression based on Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 for CT imaging (75).”
MethodInfluentialSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · cited 1×
“After evaluating features of response and resistance to MRTX1133 in vitro , we sought to investigate the efficacy of KRAS G12D inhibition in the immunocompetent, autochtho-nous KPC ( Kras LSL-G12D/ + ; Trp53 LSL-R172H/ + ; p48-Cre ) genetically engineered mouse model (GEMM) of PDAC (49).”
BackgroundHidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 2×
“…published cases of lung neuroendocrine tumor (patient 105; 14), melanoma, small cell lung cancer and spindle cell carcinoma (patients 10, 21 and 8; 19) to create a pan-cancer cohort of 132 patients with KRAS G12C mutation and displaying acquired resistance to adagrasib, sotorasib, or…”
BackgroundData-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303 · cited 1×
“54).”
Cited by
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 146
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 132
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pei, G., Min, J., Rajapakshe, K., Branchi, V., Liu, Y., Selvanesan, B. C., Thege, F. I., Sadeghian, D., Zhang, D., Cho, K. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08927-x · Cited by 148
“5), along with CAFs previously established from patients with PDAC 16,25,26 .”
Self-citationConsensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 109
Self-citationEpithelial-mesenchymal transition
Zhang, C. X., Huang, R. Y., Sheng, G., & Thiery, J. P. (2025) · Cell · doi:10.1016/j.cell.2025.08.033 · Cited by 134
Riedl, J. M., Fece de la Cruz, F., Lin, J. J., Parseghian, C., Kim, J. E., Matsubara, H., Barnes, H., Caughey, B., Norden, B. L., Morales-Giron, A. A., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.01.020 · Cited by 68
Response and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 83
Self-citationComprehensive analysis of oncogenic determinants across tumor types via multi-omics integration
Ubaid, S., Kushwaha, R., Kashif, M., & Singh, V. K. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.08.010 · Cited by 86
The future of tumor organoids in precision therapy
Kim, S., van de Wetering, M., Clevers, H. C., & Sanders, K. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.03.005 · Cited by 69
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 100
“…54% of patients had no detectable genetic mechanisms of resistance, a finding that was recapitulated in a group of KRAS LSL-G12D/+ ; TP53 LSL-R172H/+ ; p48-Cre (KPC) mice exposed to MRTX1133, suggesting that non-genetic mechanisms also have a role in resistance to KRAS-targeted therapies 378 .”
Orlen, M., Vostrejs, W. P., Sor, R., McDevitt, J. C., Kemp, S. B., Kim, I., Kramer, A. B., Shifrin, N. T., Markosyan, N., Clendenin, C., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1475 · Cited by 70
“Recently, we and others reported that small-molecule inhibition of KRAS G12D , the most common mutant allele of KRAS in PDAC (40%), is highly effective in multiple preclinical PDAC models (13, 15–17).”
Self-citationKRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 73
“Some of these include transcriptional reprogramming that changes cellular states such as epithelial-to-mesenchymal transition (164), activation of YAP/TAZ signaling (167), adeno-to-squamous cell carcinoma transition (87), and mucinous differentiation (170).”
InfluentialMolecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Skoulidis, F., Li, B. T., Langen, A. J. D., Hong, D. S., Léna, H., Wolf, J., Dy, G. K., Fontecedro, A. C., Tomasini, P., Velcheti, V., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03732-5 · Cited by 68
“In support of this finding, a mucinous transcriptional state akin to the classical subtype of pancreatic adenocarcinoma was recently reported to support long-term tumor cell persistence in response to diverse RAS inhibitors in NSCLC 44 and pancreatic ductal adenocarcinoma preclinical models 45,46 .”
Self-citationTargeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 80
“204 These fi ndings re fl ected the molecular ampli fi cation of KRAS, Yap1, Myc, Cdk6, and Abcb1a/b , as well as the coevolution of drug resistance transcriptional programs.”
Knox, J. J., O'Kane, G. M., King, D. A., Laheru, D. A., Habowski, A. N., Yu, K. H., Perez, K. J., Aguirre, A. J., Coyne, Z. L., Harvey, H. M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00436 · Cited by 62
Self-citationWhole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Knox, J. J., Jang, G. H., Grant, R. C., Zhang, A. X. W., Ma, L. X., Elimova, E. C., Jang, R., Moore, M. J., Biagi, J. J., Tehfe, M. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60808-z · Cited by 49
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 65
Emerging landscape of KRAS inhibitors in cancer treatment
Riedl, J. M., Matsubara, H., McNeil, R., Patel, P. S., de la Cruz, F. F., Gulhan, D., & Corcoran, R. B. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.01.001 · Cited by 53
Lencioni, G., Gregori, A., Toledo, B., Rebelo, R., Immordino, B., Amrutkar, M., Xavier, C. P. R., Kocijancic, A., Pandey, D. P., Perán, M., et al. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.002 · Cited by 35
Han, L., Meng, L., Liu, J., Xie, Y., Kang, R., Klionsky, D. J., Tang, D., Jia, Y., & Dai, E. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217258 · Cited by 37
Pancreatic Cancer: Pathogenesis and Clinical Studies
Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 35
Tian, L., Li, H., Cui, H., Tang, C., Zhao, P., Wang, X., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08101-1 · Cited by 31
“However, KRAS is not sensitive to the inhibition of upstream growth factor receptor signaling, while targeting downstream effector molecules is hindered by the activation of compensatory resistance mechanisms [3, 4].”
Broderick, C., Mezzadra, R., Sisso, E. M., Mbuga, F., Raghulan, R., Perez, A. C., Kulick, A. R., Jiang, L., Jiang, J., Ho, Y.-J., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1425 · Cited by 32
Self-citationPaneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer
Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.10.010 · Cited by 23
“30,31 Our findings suggest that CRC cells switch to a Paneth-like state as their survival strategy.”
Jiang, X., Wang, T., Zhao, B. X., Sun, H., Dong, Y., Ma, Y., Li, Z., Wu, Y., Wang, K., Guan, X., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101966 · Cited by 35
Self-citationNew exploration of KRASG12D inhibitors and the mechanisms of resistance
Li, Y., Zhao, J., & Li, Y. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00637-4 · Cited by 25
“The mechanism of resistance to KRAS inhibitors was comprehensively shared through clinical samples (ctDNA), and multiple in vitro and in vivo models, such as cell lines, organoids, and genetically engineered mouse models included multimodal data at the genome, transcriptome, and protein levels [12].”
Artificial intelligence in tumor drug resistance: Mechanisms and treatment prospects
Gu, J., Zhang, J., Zeng, S., Zhang, W., Xia, R., Wang, X., Zhou, Q., Guo, S., Wang, H., & Chen, Z.-S. (2025) · Intelligent Oncology · doi:10.1016/j.intonc.2025.02.001 · Cited by 26
Centonze, A., Roura, A.-J., Novillo-Font, M., Giordano, C., Hernando‐Momblona, X., Llanses, M., Prats, P., Sevillano, M., Cabot, D., Novell, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0679 · Cited by 33
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
Wang, X., Wu, J., Xiao, A., Wang, J., & Tian, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02364-0 · Cited by 29
“A median PFS of 9.8 months, a median OS of 17.7 months and an ORR of 38% were achieved [113].”
InfluentialSelf-citationAdapting systems biology to address the complexity of human disease in the single-cell era
Fischer, D. S., Villanueva, M. A., Winter, P. S., & Shalek, A. K. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00821-6 · Cited by 35
“Just as previous technological advances first enabled systems biology, ongoing measurement and modelling advances will drive progress in multiscale systems biology.”
Self-citationTreatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?
Krupa, K., Fudalej, M. M., Włoszek, E., Miski, H., Badowska-Kozakiewicz, A. M., Mękal, D., Budzik, M. P., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17152453 · Cited by 25
“Dilly et al., in a study published in 2024, identified both genetic and non-genetic adaptations, including the activation of PI3K-AKT-mTOR signaling pathways and the induction of EMT, as key contributors to therapeutic resistance in PDAC [55].”
Aguirre, A. J., Stanger, B. Z., & Maitra, A. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1926 · Cited by 18
Self-citationZhang, X., Du, Y., Behrens, A., & Lan, L. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.07.002 · Cited by 25
De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer
Zhang, H., Santana-Codina, N., Yu, Q., Poupault, C. L., Campos, C., Qin, X., Sindoni, N., Ciscar, M., Padhye, A., Kuljanin, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61242-x · Cited by 23
“ABBV-637, an ADC consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to an inhibitor of BCL-X L , and ABBV-155, an ADC composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated to a BCL-X L…”
Self-citationMcAndrews, K. M., Paradiso, F., Stalnecker, C. A., Selvanesan, B. C., Thege, F. I., Peng, D. H., Diaz, B. A. M., Sugimoto, H., Patel, S. I., Mahadevan, K. K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt5511 · Cited by 18
Self-citationAttili, I., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., Passaro, A., & de Marinis, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102957 · Cited by 20
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 21
Liaki, V., Barrambana, S., Kostopoulou, M., Lechuga, C. G., Zamorano-Domínguez, E., Acosta, D., Morales-Cacho, L., Álvarez, R., Sun, P., Rosas-Pérez, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2523039122 · Cited by 37
RetractedSevrin, T., Imoto, H., Robertson, S. A., Rauch, N., Dyn'ko, U., Koubova, K., Wynne, K. J., Kölch, W., Rukhlenko, O. S., & Kholodenko, B. Ν. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114710 · Cited by 17
“52,53”
BackgroundMolnár, E., Baranyi, M., Szigeti, K. A., Hegedüs, L., Bordás, F., Gábriel, Z., Petényi, G., Tóvári, J., Hegedűs, B., & Tímár, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611948 · Cited by 18
Alagesan, B., Varghese, A. M., Ang, C., Gutiérrez, M., Kamar, M., Passhak, M., Geva, R., Yarom, N., Lahav, M., Ligresti, R., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3189 · Cited by 21
Knoll, N., Masser, S., Bordas, B., Ebright, R. Y., Li, G., Kesar, D., Destefanis, E., Kania, N., Rodriguez, D. J., Jen, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1464 · Cited by 15
Self-citationFunctional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity
Kovalski, J. R., Sarioglu, G., Subramanyam, V., Hernandez, G. A., Rademaker, G., Osés-Prieto, J. A., Slota, M. J., Mohan, N., Yiakis, K., Liu, I., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-024-01604-7 · Cited by 13
“In particular, Myc is a key driver of cancer cell growth and adaptation to therapy, leading to drug resistance and tumour progression 14,16–18 .”
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Hoang, T. A., & Tsang, E. S. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-024-01149-w · Cited by 18
“Recent preclinical studies in mice have revealed that combining traditional chemotherapy with the novel KRAS inhibitor, MRTX1133, may significantly enhance therapeutic efficacy against pancreatic cancer [60, 61].”
Ohara, Y., Liu, H., Moreno, P., Suzuki, S., & Hussain, S. P. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108946 · Cited by 18
Experimental models of pancreas cancer: what has been the impact for precision medicine?
Pantazopoulou, V., Kubota, C. S., Ogawa, S., Gulay, K. C. M., Lin, X., Song, H., Weitz, J., Tiriac, H., Lowy, A. M., & Engle, D. D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191945 · Cited by 18
“Despite its limitations, this model has been used to evaluate the effect of targeted therapies in combination with chemotherapy against metastases (32).”
Xu, C., Lin, W., Zhang, Q., Ma, Y., Wang, X., Guo, A., Zhou, Z., Zhou, Z., Song, W., Zhao, Z., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00972-y · Cited by 15
“The emergence of resistance is accompanied by the amplifications of Kras, Yap1, Myc, and Cdk6/Abcb1a/b, as well as the co-evolution of drug-resistant transcriptional programs (Dilly et al. 2024).”
BackgroundZhang, E., Ding, X., Zhang, J., Liu, W., Liu, G., Li, M., Liu, X., Wang, Y., Zhang, F., Li, B., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217887 · Cited by 12
Shenoy, A., Yousif, A., & Hussain, M. D. (2025) · Cancers · doi:10.3390/cancers17081319 · Cited by 14
“Resistance to KRAS inhibitors remains a major challenge, often resulting from various mechanisms, including tumor heterogeneity and the survival of subpopulations of cells that persist despite KRAS inhibition [70,71].”
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
Wu, J., Xie, K., Zhang, Y., Zhang, W., Cheng, R., Zhang, Y., Xia, Y., Liu, T., Yin, R. H., Qiu, Y., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03369-9 · Cited by 11
The KRAS mutational spectrum and its clinical implications in pancreatic cancer
Perelli, L., Genovese, G., & Draetta, G. F. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.001 · Cited by 13
Solanki, H. S., Shah, H., Imbody, D. J., Desai, B., Kato, R., Miroshnychenko, D., Stern, Y. E., Majumder, A., Sarcar, B., Xieraili, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0600 · Cited by 12
Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
Chareddy, Y. S., Huggins, H. P., Sahoo, S. S., Stanland, L. J., Gutierrez-Ford, C., Whately, K. M., Edatt, L., Azam, S. H., Fleming, M. C., Im, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187204 · Cited by 12
“Clinical resistance to KRAS inhibitors is well documented, with MAPK effector upregulation, MYC amplification, and YAP/ TAZ signaling emerging as key players in driving resistance (67, 68).”
Fan, H., Chen, H., Song, H., Li, C., Wang, Y., Zhao, Z., Guo, Q., Li, X., Liu, M., Sun, T., et al. (2025) · Advanced Science · doi:10.1002/advs.202507118 · Cited by 18
Peng, L., Liang, Y., Guo, X., Zhang, Q. W., Gao, Z., Kong, X., Zhang, H., Zhu, B., & Cui, D. (2025) · Nanoscale Advances · doi:10.1039/d5na00513b · Cited by 16
“3 8 At the molecular level, PDAC is de ned by recurrent genetic alterations — most notably KRAS activating mutations in over 90% of cases, 9 and inactivation of key tumor suppressors such as TP53, CDKN2A, and SMAD4.”
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment
Arnold, F., Vecchio, A. D., Hussain, Z., & Sherman, M. H. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00905-9 · Cited by 17
Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Ozawa, H., Takahashi, K., Motegi, T., Jacobi, J. J., Bhattacharya, A., Shigeta, K., Takamori, S., Onishi, M., Luan, Z., Fukuda, K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2333 · Cited by 14
“For organoids, the CellTiter-Glo 3D Cell Viability Assay (Promega) was used as described (26).”
InfluentialSelf-citationOpposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinoma
Fort, G., Arnold, H., Camolotto, S. A., O’Toole, K. T., Tariq, R., Waters, A. K., Gillis, K., & Snyder, E. L. (2025) · Genes & Development · doi:10.1101/gad.352742.125 · Cited by 14
“Moreover, this observation provides a likely molecular mechanism for the observation that KRAS inhibition induces therapeutically relevant alveolar identity programs in LUAD (Li et al. 2024), as these programs are largely NKX2-1-dependent (Snyder et al. 2013; Little et al. 2019, 2021).”
InfluentialToyokuni, E., Horinaka, M., Nishimoto, E., Yoshimura, A., Fukui, M., & Sakai, T. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0831 · Cited by 10
Applications and challenges of patient-derived organoids in hepatobiliary and pancreatic cancers
Hu, J.-W., Pan, Y., Zhang, X., Li, J., & Jin, Y. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i20.106747 · Cited by 10
Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches
Xu, Y., Peng, X. L., East, M. P., McCabe, I. C., Stroman, G. C., Jenner, M. R., Chan, P., Morrison, A. B., Shen, E. C., Hererra, S. G., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1480 · Cited by 10
Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Wang, L., Wei, D., Li, S., & Jiang, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03569-x · Cited by 8
“Clinical genomic investigations of KRAS G12C -mutant PDAC patients treated with adagrasib or sotorasib identified characteristic acquired resistance alterations, including secondary PIK3CA and KRAS mutations, genomic amplifications of KRAS G12C , MYC , MET , EGFR , and CDK6 [128].”
Integrative genomic identification of therapeutic targets for pancreatic cancer
Guo, J. A., Gong, D. H., Evans, K. E., Takahashi, K., Jambhale, A. D., Shiau, C., Yu, P. Z., Wang, S., Wu, W., Chugh, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116191 · Cited by 9
“Strikingly, our signatures strongly predicted the drug sensitivity of KRAS G12D PDAC cell lines 74 to MRTX1133, a KRAS G12D targeting small molecule inhibitor in clinical trials (Figure 4C), and to RMC6236, 15 a multi-selective KRAS inhibitor in clinical trials.”
Self-citationRecent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Sobhani, N., Pittacolo, M., D’Angelo, A., & Marchegiani, G. (2025) · Cancers · doi:10.3390/cancers17040704 · Cited by 14
“This variability complicates the development of inhibitors that can effectively target multiple KRAS variants across diverse tumor types [122–124].”
Predictive biomarkers of pancreatic cancer metastasis: A comprehensive review
Chen, M., Liu, H., Xiao, Y., Liang, R., Xu, H., Hong, B., & Qian, Y. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120176 · Cited by 8
Different Cytotoxic Effects of Cisplatin on Pancreatic Ductal Adenocarcinoma Cell Lines
Muscella, A., Cossa, L. G., Stefàno, E., Rovito, G., Benedetti, M., Fanizzi, F. P., & Marsigliante, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413662 · Cited by 12
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“Genetic alterations, especially secondary RAS mutations, have been identified as one of the most common mechanisms of acquired resistance to KRAS inhibitors in patients [51, 53 – 57].”
Reyes, J., Priore, I. S. D., Chaikovsky, A. C., Pasnuri, N., Elhossiny, A. M., Park, J., Weiler, P., Krause, T., Moorman, A. R., Snopkowski, C., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.032 · Cited by 21
Self-citationLactylation and acetylation: parallel paths, divergent deeds, and research dilemmas
Jiang, W., Chen, Y., Lin, S., Liu, Y., & Liao, X. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07877-w · Cited by 8
“In KRAS inhibitor-resistant models, sustained RAS activation aggravates the lactate/acetyl-CoA ratio imbalance, culminating in metabolism-dependent post-translational modification (PTM) dysregulation [38].”
Stahlhut, C. E., Maciag, A. E., Sullivan, K. A., Singh, K., Gitego, N., Zhang, Z., Chan, A. H., Sharma, A. K., Alexander, P., Shu, J., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1280 · Cited by 12
“Bypass signaling through RTKs, including EGFR, can activate NRAS, HRAS, and downstream MAPK pathway components, as well as cross-activate the PI3K pathway to confer resistance to KRAS inhibitors (26, 33).”
Principe, D. R., Becker, J. H., Metropulos, A. E., Marinelarena, A. M., Pham, T. D., Aissa, A. F., & Munshi, H. G. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0483 · Cited by 10
Chen, T., Yu, H., Wang, K., Qin, G., Zhao, Y., Liang, X., Li, Y., Zou, T., Liu, J., Zhao, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci195814 · Cited by 7
“In addition, PDAC with gene alterations, such as PTEN , NF1 , and RB1 , may exhibit intrinsic resistance to MRTX1133 (5, 38), while upregulation of immune checkpoint markers (such as CTLA4 , LAG3 ) and cellular heterogeneity further exacerbate resistance (7, 8, 37, 38).”
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
Lim, S.-A., Todd, H., Goodhart, G., Chang, W.-H., Amparo, A. M., Bridgens, R., Dilly, J., Park, S. J., Beal, R. M., Shehadeh, S. M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1835 · Cited by 12
“We recently reported that in humans and animal models with PDAC, MYC amplification is a putative resistance driver to KRASi (10, 17).”
InfluentialSelf-citationBian, Y., Shan, G., Bi, G., Xu, Z., Liang, J., Yan, Y., Guo, W., Sui, Q., Yi, Y., Shi, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65441-4 · Cited by 17
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 16
Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer
Gong, D. H., Liu, R., Cui, Y., Rhodes, M., Bae, J. W., Beechem, J., & Hwang, W. L. (2025) · Science Advances · doi:10.1126/sciadv.adx0632 · Cited by 7
“EMT signatures were previously found to be strongly enriched in mouse models of PDAC treated to resistance with MRTX1133 ( 37 ).”
Pan‐ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer
Buchloh, J., Spitzner, M., Zimmermann, H., Fang, X., Contreras, C. T., Schneider, C., de Oliveria, T., Küffer, S., Linnebacher, M., Rühlmann, F., et al. (2025) · United European Gastroenterology Journal · doi:10.1002/ueg2.70086 · Cited by 6
Srinivasan, D., Gout, J., Kleger, A., & Roger, É. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115697 · Cited by 11
Enhancing chemosensitivity in pancreatic cancer: Novel strategies to overcome therapeutic resistance
Luo, W., Zhang, M., Chen, H., Wang, J., Cao, Z., Yang, G., Qiu, J., Liu, Y., Fu, Y., Tao, J., et al. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000098 · Cited by 7
Self-citationBarrambana, S., Zamorano-Domínguez, E., Liaki, V., & Guerra, C. E. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115652 · Cited by 10
Campbell, B. A., Solinas, D., Blackford, A. L., Molin, M. D., Purchla, J., McPhaul, T. J., Chidambaram, S., Cameron, J. L., Lin, M., Hruban, R. H., et al. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006794 · Cited by 8
Abuelafia, A. M., Santofimia‐Castaño, P., Estarás, M., Grasso, D., Chuluyán, E., Lomberk, G. A., Urrutia, R. A., Dusetti, N., Fraunhoffer, N. A., & Iovanna, J. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102421 · Cited by 7
“Several studies have demonstrated that KRAS inhibition can sensitize PDAC cells to gemcitabine treatment both in vitro [28,29] and in vivo [30 – 32] Additionally, the RAF/MEK/ERK pathway has been implicated in resistance to Gemcitabine, and its inhibition has been shown to enhance the drug ’ s…”
FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development
Tonelli, C., Deschênes, A., Gaeth, V. A., Jensen, A., Vithlani, N., Yao, M. A., Zhao, Z., Park, Y., & Tuveson, D. A. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4576 · Cited by 13
Aronchik, I., Kar, S., Zhuang, Y., Ahler, E., Lai, L., Seshadri, V., Yang, Y. C., Bulle, A. S., Ménard, M., Nayak, B., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04537-w · Cited by 32
“Although prevalent in GEMMs, MYC amp is less frequent in KRAS G12C(OFF) inhibitor-treated PDAC and in this cohort 19 .”
InfluentialSelf-citationHibshman, P. S., Stalnecker, C. A., Klomp, J. A., Drizyte‐Miller, K., Klomp, J. E., Edwards, A. C., Pita, L. M., Hodge, R. G., Diehl, J. N., Mouery, R. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adu7145 · Cited by 10
Surana, R., Morgado, M., Somasundaram, A., Bockorny, B., Weekes, C. D., Coleman, E. C., Bird, A., Wang, J., Williams, H. L., Zheng, H., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00332 · Cited by 12
Self-citationEvolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS
Dorandish, S., Bhayekar, K., Singh, A., Kushwaha, N. D., Malin, E., Serafimovski, S., Kelm, J. M., Gavande, N. S., & Lakkaniga, N. R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00169b · Cited by 7
The Far Side of Resistance to RAS Inhibitors
Marasco, M., & Misale, S. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1153 · Cited by 5
Schmitt, A. M., Gätje, F. B., Tran, M. Y. R., Midelashvili, T., Xu, X., Fleischer, J. R., Spahn, H., Lai, K., Tacke, T., Younes, S., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02628-3 · Cited by 5
“Ultimately, this work demonstrates that PDAC cannot be adequately understood or treated by bulk, single-label molecular subtyping alone.”
Lin, Q., Morales-Giron, A. A., Sander, C., Curtis, J. M., Barnes, H., Patel, P. S., de la Cruz, F. F., Riedl, J. M., Matsubara, H., Nakamura, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1788 · Cited by 11
“However, although a potential role for EGFR in adaptive resistance, similar to that in colorectal cancer, has been suggested in PDAC (36–38), and this strategy is under evaluation for PDAC in several clinical trials (NCT06227377, NCT07026916), the contributions and mechanisms of adaptive resistance…”
Xu, X., Chen, X., Xu, R., Huo, Z., Li, C., Nowsheen, S., Aziz, K., Yao, F., Lou, Z., & Deng, M. (2026) · Nature Communications · doi:10.1038/s41467-026-69695-4 · Cited by 9
“Mutations in KRAS, such as the KRAS G12D/C variant, lead to constitutive activation of oncogenic pathways, including the Ras/Raf/MEK/ERK and PI3K/AKT/ mTOR signaling cascades 8 – 10 .”
Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
May, M. S., Park, W., & O'Reilly, E. M. (2026) · Drugs · doi:10.1007/s40265-026-02295-0 · Cited by 7
“Further investigation is needed to determine the optimal therapeutic mechanisms of action, claudin 18.2 positivity cutoffs and combinations required for successful claudin-targeting therapy [101, 114].”
InfluentialHao, J., Zakershahrak, M., Ly, P., Le, A. D., Yu, W., Gates, J. C., & Chen, C. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07786-y · Cited by 6
“In these contexts, the shift toward YAP/TAZ dependence often accompanies transcriptional reprogramming and the emergence of drug-tolerant mesenchymal or basal-like cell states [173].”
Genomic evolution of pancreatic cancer at single-cell resolution
Zhang, H., Sashittal, P., Karnoub, E.-R. R., Jakatdar, A., Umeda, S., Hong, J., Noronha, A. M., Cardenas, A., Erakky, A., McIntyre, C. A., et al. (2026) · Nature Genetics · doi:10.1038/s41588-025-02468-9 · Cited by 10
“Nonetheless, responses to these therapies have been mixed with some patients’ showing no benefit 13 .”
Bonsor, D. A., Finci, L. I., Potter, J. R., Young, L. C., Wall, V. E., de Salazar, R. G., Geis, K. R., Stephens, T., Finney, J., Nissley, D. V., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68319-1 · Cited by 8
“Innormalcells,thepredominantRASisoform(MRASorcanonicalH/K/ NRAS)thatassembleswithSHOC2andPP1CforRAFactivationremains unclear, due to redundancy among RAS proteins 14,45 .”
Ghanwatkar, Y., Mahto, S., Chittipolu, A., Ramanathan, R., Shrestha, P., & Mahato, R. I. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.12.049 · Cited by 8
Cunniff, P. J., Sivetz, N., Skopelitis, D. S., Klingbeil, O., Toobian, D., Maia-Silva, D., Egeblad, M., & Vakoc, C. R. (2025) · Nature Communications · doi:10.1038/s41467-025-66007-0 · Cited by 8
“For example, a RUVBL1/2 inhibitor might be combined with an oncogene-targeted therapy toprevent the emergence of a drug-tolerant lineage state 17,18,77,78 .”
Köse, H., Schneeweis, C., Putze, P., Contreras, C. T., Ferreiro, L., Witte, L., Deidda, I., Herzberg, F., Ebert, S., Jakubík, J., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.018 · Cited by 6
“4 Furthermore, the finding that oncogenic PI3K-signaling can compensate KRAS-dependency to initiate and drive carcinogenesis and tumor progression in murine PDAC models 5,6 highlights the PI3K pathway’s significance as a therapeutic target.”
Metadata
- Authors
- Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., Uribe, G. A., Yang, A., Kapner, K. S., Hambitzer, F. P., Qiang, L., Feng, H., Geisberg, J., Wang, J., Evans, K. E., Lyu, H., Schalck, A., Feng, N., Lopez, A. M., Bristow, C. A., Kim, M. P., Rajapakshe, K. I., Bahrambeigi, V., Roth, J. A., Garg, K., Guerrero, P. A., Stanger, B. Z., Cristea, S., Lowe, S. W., Baslan, T., Van Allen, E. M., Mancias, J. D., Chan, E., Anderson, A., Katlinskaya, Y. V., Shalek, A. K., Hong, D. S., Pant, S., Hallin, J., Anderes, K., Olson, P., Heffernan, T. P., Chugh, S., Christensen, J. G., Maitra, A., Wolpin, B. M., Raghavan, S., Nowak, J. A., Winter, P. S., Dougan, S. K., & Aguirre, A. J.
- Affiliations
- Broad Institute (US)
- Harvard University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- 3Harvard Medical School, Boston, Massachusetts.
- 8Exact Sciences, Redwood City, California.
- University of Pennsylvania (US)
- Memorial Sloan Kettering Cancer Center (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Amgen (United States) (US)
- Mirati Therapeutics (United States) (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Aguirre, Andrew J.
- ORCID
- Dilly, Julien
- Hoffman, Megan T.
- Abbassi, Laleh
- Li, Ziyue
- Paradiso, Francesca
- Parent, Brendan D.
- Hennessey, Connor J.
- Jordan, Alexander C.
- Morgado, Micaela
- Dasgupta, Shatavisha
- Uribe, Giselle A.
- Yang, Annan
- Kapner, Kevin S.
- Hambitzer, Felix P.
- Qiang, Li
- Feng, Hanrong
- Geisberg, Jacob
- Wang, Junning
- Evans, Kyle E.
- Lyu, Hengyu
- Schalck, Aislyn
- Feng, Ningping
- Lopez, Anastasia M.
- Bristow, Christopher A.
- Kim, Michael P.
- Rajapakshe, Kimal I.
- Bahrambeigi, Vahid
- Roth, Jennifer A.
- Garg, Kavita
- Guerrero, Paola A.
- Stanger, Ben Z.
- Cristea, Simona
- Lowe, Scott W.
- Baslan, Timour
- Van Allen, Eliezer M.
- Mancias, Joseph D.
- Chan, Emily
- Anderson, Abraham
- Katlinskaya, Yuliya V.
- Shalek, Alex K.
- Hong, David S.
- Pant, Shubham
- Hallin, Jill
- Anderes, Kenna
- Olson, Peter
- Heffernan, Timothy P.
- Chugh, Seema
- Christensen, James G.
- Maitra, Anirban
- Wolpin, Brian M.
- Raghavan, Srivatsan
- Nowak, Jonathan A.
- Winter, Peter S.
- Dougan, Stephanie K.
- Aguirre, Andrew J.
- Venue
- Cancer Discovery
- Published
- 2024-07-05
- Volume
- 14
- Issue
- 11
- Pages
- 2135-2161
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC11528210
- OpenAlex
- W4400416998
- Semantic Scholar
- 5523d24bee9ee8e296cf3c0bde017f0d9fee7408
- Cited by
- 308
- References
- 100
- Citations by year
- 2026: 162 · 2025: 129 · 2024: 17
- FWCI
- 54.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Break Through Cancer
- National Cancer Institute (R01 CA276268, U01 CA274276, P50CA127003, P50CA221707, R01CA218230)
- Hale Family Center for Pancreatic Cancer Research
- Lustgarten Foundation
- Pancreatic Cancer Action Network
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS inhibition, acquired drug resistance, pancreatic ductal adenocarcinoma, KRAS G12C, KRAS G12D, adagrasib, sotorasib, MRTX1133, PIK3CA mutation, PI3K/AKT/mTOR pathway, epithelial-mesenchymal transition, KPC mouse model, organoid models, combination therapy, chemotherapy, YAP, c-Myc, CDK6, non-genetic resistance, drug resistance mechanisms
- MeSH terms
- Animals, Humans, Mutation, Pancreatic Neoplasms, Pyrimidines, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.